U.S. markets open in 2 hours 28 minutes
  • S&P Futures

    4,258.00
    +3.25 (+0.08%)
     
  • Dow Futures

    34,370.00
    -11.00 (-0.03%)
     
  • Nasdaq Futures

    14,142.00
    +17.25 (+0.12%)
     
  • Russell 2000 Futures

    2,322.70
    -0.90 (-0.04%)
     
  • Crude Oil

    71.47
    +0.59 (+0.83%)
     
  • Gold

    1,867.10
    +1.20 (+0.06%)
     
  • Silver

    27.79
    -0.25 (-0.89%)
     
  • EUR/USD

    1.2123
    0.0000 (-0.00%)
     
  • 10-Yr Bond

    1.5010
    0.0000 (0.00%)
     
  • Vix

    16.54
    +0.89 (+5.69%)
     
  • GBP/USD

    1.4086
    -0.0022 (-0.15%)
     
  • USD/JPY

    110.0600
    -0.0010 (-0.00%)
     
  • BTC-USD

    40,000.56
    +644.45 (+1.64%)
     
  • CMC Crypto 200

    1,001.21
    +32.37 (+3.34%)
     
  • FTSE 100

    7,168.49
    +21.81 (+0.31%)
     
  • Nikkei 225

    29,441.30
    +279.50 (+0.96%)
     

Precision BioSciences Shares Move Higher As ARCUS Platform Shows Promising Gene Editing Approach For Transthyretin Amyloidosis

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Precision BioSciences Inc (NASDAQ: DTIL) has announced new in vivo data using ARCUS genome editing platform resulting from a preclinical research collaboration with investigators at the University of Pennsylvania.

  • Data were presented at the 2021 American Society of Genetic & Cell Therapy (ASGCT) Annual Meeting.

  • Researchers reported preclinical results using ARCUS to knock out the transthyretin (TTR) gene responsible for transthyretin amyloidosis (ATTR), a rare disease that leads to peripheral neuropathy or cardiomyopathy.

  • In ARCUS-treated no-human primates (NHPs), high levels of genomic editing were achieved, resulting in substantial and persistent serum TTR reductions.

  • Up to 46% indels were found at the genomic DNA locus, translating to ~80% editing of the TTR messenger RNA transcripts maintained between liver biopsies collected at 18 and 128 days post-AAV administration.

  • Researchers found that high editing efficacy of the TTR gene was reflected in serum TTR levels, where there was an associated reduction of greater than 95% by day 21 post-vector administration in three out of the four ARCUS-treated NHPs.

  • These serum TTR reductions endured to 250 days after a single AAV administration.

  • Price Action: DTIL shares are up 11.5% at $9 during the market trading session on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.